The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
Choroideremia (CHM) is a rare, X-linked recessive retinal dystrophy caused by mutations in the CHM gene. CHM is ubiquitously expressed in human cells and encodes Rab escort protein 1 (REP1). REP1 plays a key role in intracellular trafficking through the prenylation of Rab GTPases, a reaction that ca...
Main Authors: | Patrício, M, Barnard, A, Cox, C, Blue, C, MacLaren, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2018
|
Similar Items
-
The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by In Vitro Prenylation of RAB6A
by: Maria I. Patrício, et al.
Published: (2018-06-01) -
Prenylation of rab6a as a potency assay for choroideremia gene therapy
by: Patricio, M, et al.
Published: (2017) -
Choroideremia: molecular mechanisms and development of AAV gene therapy
by: Patrício, M, et al.
Published: (2018) -
Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.
by: Barnard, A, et al.
Published: (2014) -
Rab GTPase prenylation hierarchy and its potential role in choroideremia disease.
by: Monika Köhnke, et al.
Published: (2013-01-01)